Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center
Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center
Read more on Microdose.
[bsa_pro_ad_space id=2]
ADVERTISEMENT
[bsa_pro_ad_space id=2]
ADVERTISEMENT